The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries

Spuls, Phyllis I.; Gerbens, L. A. A.; Apfelbacher, Christian; Wall, Dmitri; Arents, B.W.M.; Barbarot, S.; Roberts, Amanda; Deleuran, Mette; Middelkamp‐Hup, Maritza A.; Vestergaard, Christian; Weidinger, Stephan; Schmitt, Jochen; Irvine, Alan D.; Flohr, Carsten

doi:10.1016/j.jid.2017.05.014

Cited by 26 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The AD should be treated according to current guidelines and position papers, and the outcome should be documented in registries such as the national AD treatment registries that belong to international TREAT (TREatment of ATopic eczema registry taskforce (https://treat-registry-task force.org). 130…”

Section: Unplanned Pregnancy During Systemic Treatmentmentioning

confidence: 99%

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Vestergaard

Wollenberg

Barbarot

et al. 2019

Acad Dermatol Venereol

166

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up‐to‐date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

show abstract

Section: Unplanned Pregnancy During Systemic Treatmentmentioning

confidence: 99%

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Vestergaard

Wollenberg

Barbarot

et al. 2019

Acad Dermatol Venereol

166

View full text Add to dashboard Cite

show abstract

“…Continuation of conventional systemic immunosuppressants in the first weeks of dupilumab treatment seems to be an effective and safe way to transition to monotherapy with dupilumab but this needs to be studied in larger numbers of patients. This emphasizes the importance of the introduction of registries such as the national registries of the TREatment of ATopic eczema (TREAT) Registry Taskforce for monitoring systemic treatments in daily practice …”

Section: Discussionmentioning

confidence: 99%

“…In addition to acquiring short‐term follow‐up data, continuous collection of real‐world and standardized data is important in order to evaluate the effectiveness and safety of dupilumab treatment in daily practice in the long term. The TREAT Registry Taskforce (http://treat-registry-taskforce.org/ ) is an international network of national registries that aim to collect such data . Such registries intend to gather observational real‐world data of paediatric and adult patients with AD and receiving phototherapy and systemic therapy, using a harmonized dataset including time points .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary Background Dupilumab is the first biologic registered for the treatment of moderate‐to‐severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, there are limited daily practice data available for dupilumab, especially when it is combined with systemic immunosuppressants. Objectives To evaluate dupilumab treatment in daily practice in patients with AD. Methods In this observational cohort study, we prospectively included all adult patients with AD who had been treated with dupilumab in two university hospitals in the Netherlands. Concomitant systemic immunosuppressive treatment was monitored. Physician‐reported outcome measures and patient‐reported outcome measures (PROMs) after ≥ 12 weeks of follow‐up were analysed. We used a linear mixed‐effects model to determine changes in scores during follow‐up. Results Ninety‐five patients were included. Of these, 62 patients were using systemic immunosuppressants at baseline; the use of systemic immunosuppressants was continued during dupilumab treatment in 43 patients. From baseline to 16 weeks of treatment, the estimated mean Eczema Area and Severity Index score (0–72) decreased from 18·6 [95% confidence interval (CI) 16·0–21·4)] to 7·3 (95% CI 5·4–10·0), and the estimated mean PROMs showed a decrease of 41–66%. Investigator's Global Assessment 0 or 1 (clear/almost clear) was reached in 38% of the patients. Five patients discontinued dupilumab treatment due to side‐effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex virus (HSV) reactivation were reported in 62% and 8% of the patients, respectively. Conclusions Dupilumab treatment in daily practice shows a clinically relevant improvement of physician‐reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns. What's already known about this topic? Dupilumab has been shown to be an efficacious treatment for atopic dermatitis in several clinical trials. However, it is known that there may be considerable differences in patient characteristics and treatment responses between clinical trials and daily practice. What does this study add? This study presents the first experience with dupilumab treatment in 95 patients with atopic dermatitis in daily practice in two Dutch university hospitals. Less stringent inclusion and exclusion criteria and follow‐up schedules, in contrast to those used in clinical trials, might better represent daily practice. Dupilumab treatment shows a clinically relevant improvement of physician‐ and patient‐reported outcome measures; besides patient‐reported eye symptoms (in 59 of 95 patients; 62%) and an apparent increase in orofacial (nonocular) herpes simplex virus reactivation (eight of 95 patients; 8%), there were no other safety concerns during follow‐up up to 16 weeks of dupilumab treatment.

show abstract

“…Inspired by the psoriasis registries and the German atopic eczema registry TREATgermany, several national atopic eczema registries are currently being started or planned in Europe and beyond. The cooperation of the different national eczema registries and the a priori harmonization of data collection across registries offer a unique chance to work together efficiently and collaboratively through the research agenda for moderate‐to‐severe atopic eczema to optimize further the clinical care of patients with this common condition.…”

mentioning

confidence: 99%

After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?

Schmitt

2018

Br J Dermatol

View full text Add to dashboard Cite

show abstract

The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries

Cited by 26 publications

References 15 publications

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?

Contact Info

Product

Resources

About